We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+8.1%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$377M
AUM Growth
-$57.5M
(-13%)
Cap. Flow
-$56.5M
Cap. Flow
% of AUM
-14.97%
Top 10 Holdings %
Top 10 Hldgs %
44.25%
Holding
64
New
18
Increased
9
Reduced
13
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$17.1M |
| 2 |
CELG
Celgene Corp
CELG
|
+$15.2M |
| 3 |
Akebia Therapeutics
AKBA
|
+$9.63M |
| 4 |
Heron Therapeutics
HRTX
|
+$8.36M |
| 5 |
Omeros
OMER
|
+$7.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$38.6M |
| 2 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$21.9M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$20.5M |
| 4 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$16.5M |
| 5 |
IDIX
IDENIX PHARMACEUTICALS INC
IDIX
|
+$15.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Acadia Pharmaceuticals
ACAD
$4.55B
| $1.13M | 0.3% |
50,000
-250,000
| -83% | -$5.22M |
|
52
Curis
CRIS
$9.67M
| $1.12M | 0.3% |
+300
| New | +$1.22M |
|
53
SCYNEXIS
SCYX
$37M
| $802K | 0.21% |
+1,250
| New | +$875K |
|
|
AKTX
54
Akari Therapeutics
AKTX
$14M
| $639K | 0.17% |
13
| – | – |
|
55
Biogen
BIIB
$30.7B
| – | – |
-10,000
| Closed | -$3.06M |
|
|
56
BioMarin Pharmaceuticals
BMRN
$11.7B
| – | – |
-300,000
| Closed | -$20.5M |
|
57
Geron
GERN
$860M
| – | – |
-1,587,000
| Closed | -$3.13M |
|
58
Pacira BioSciences
PCRX
$1.06B
| – | – |
-50,000
| Closed | -$3.5M |
|
59
Prothena Corp
PRTA
$440M
| – | – |
-350,000
| Closed | -$13.4M |
|
|
ICPT
60
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| – | – |
-50,000
| Closed | -$16.5M |
|
|
ACGN
61
DELISTED
Aceragen Inc
ACGN
| – | – |
-2,944
| Closed | -$1.63M |
|
|
CBST
62
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| – | – |
-300,000
| Closed | -$21.9M |
|
|
IDIX
63
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
| – | – |
-2,500,000
| Closed | -$15.1M |
|
|
MDVN
64
DELISTED
MEDIVATION, INC.
MDVN
| – | – |
-1,200,000
| Closed | -$38.6M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Cormorant Asset Management held 64 positions worth $377M, down 13% from $435M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Cormorant Asset Management withdrew a net $56.5M in Q2 2014, closing 10 positions and reducing 13 holdings. Its most notable exit was MEDIVATION, INC., an estimated $38.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 70% a quarter earlier.
Against the trend, Cormorant Asset Management opened a new position in QUESTCOR PHARMA INC worth $18.5M.
- Cormorant Asset Management's largest Q2 2014 buy was QUESTCOR PHARMA INC: 200,000 shares worth $18.5M.
- Cormorant Asset Management added most to Omeros in Q2 2014, an estimated $7.86M increase.
- Cormorant Asset Management's biggest Q2 2014 reduction was PTC Therapeutics, cutting an estimated $8.56M.
- Cormorant Asset Management fully exited MEDIVATION, INC. in Q2 2014, selling an estimated $38.6M.
- Cormorant Asset Management's ten largest holdings make up 44% of its $377M portfolio in Q2 2014.
- Cormorant Asset Management opened 18 new positions and closed 10 in Q2 2014.
- Cormorant Asset Management's portfolio value fell 13% quarter-over-quarter to $377M.
Based on Cormorant Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.